HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)
HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 price objective on the specialty pharmaceutical company’s stock. Several other equities research analysts have also weighed in on KALV. Bank of America began coverage on shares […]
HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 price objective on the specialty pharmaceutical company’s stock. Several other equities research analysts have also weighed in on KALV. Bank of America began coverage on shares […]
